secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001493152-25-001389
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte amends lease; terminates extension right, sets expiry Oct 2027, schedules $1.7M LC reduction
--------------------------------------------------------------------------------

- Amendment entered Jan 2, 2025 with Induce Biologics and landlord Cushing Ventures.
- Original lease expires Oct 31, 2027; all extension rights cancelled.
- Letter of credit reduced by $60,714.29/month starting July 1, 2025 from $1.7M.
- Reduction contingent on no continuing default; no assurance of reduction.
- Reductions correspond to restricted cash on balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315225001389/0001493152-25-001389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315225001389/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer